Education
About Us
Working with TipRanks
Follow Us
Biome Australia Ltd (AU:BIO)
ASX:BIO
BIO Stock Chart & Stats
AU$0.40
-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.40
-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.38 - AU$0.63
Previous CloseN/A
Volume242.26K
Average Volume (3M)278.69K
Market Cap
AU$89.04M
Enterprise ValueAU$89.23M
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)19.7
Beta1.25
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding222,609,240
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.12
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained 16% top-line growth indicates durable demand for Biome's probiotic portfolio and effective channel penetration. Over 2-6 months this supports repeat orders, stronger negotiating leverage with pharmacy/practitioner partners, and a base for margin expansion as fixed costs are absorbed.
High Gross MarginA ~61% gross margin signals strong product economics and pricing power in the microbiome category. This structural advantage allows Biome to fund marketing, R&D and channel development while maintaining profitability resilience against modest COGS or pricing pressure over the medium term.
Manageable LeverageModerate leverage (D/E ~0.66) combined with positive ROE suggests the capital structure is not overly strained. This provides financial flexibility to invest in distribution and product development while retaining capacity to raise capital or service debt without immediate strain on operations.
Bears Say
Negative Operating Cash FlowNegative operating cash flow shows difficulty converting accounting earnings into cash, creating reliance on financing or working capital cycles to fund growth. Over the next 2-6 months this limits reinvestment capacity and heightens execution risk if sales seasonality or receivables worsen.
Thin Net ProfitabilityA sub-2% net margin despite high gross margins indicates operating and overhead costs materially erode profitability. Structurally weak bottom-line conversion reduces retained earnings available for strategic initiatives and makes the business sensitive to modest revenue or cost shocks.
Concentrated Domestic DistributionHeavy reliance on Australian pharmacy, practitioner and wholesale channels concentrates market and channel risk. Limited geographic diversification and a small team (30 employees) constrain scaling, expose revenue to local policy or banner negotiations, and raise execution risk over the medium term.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.38 and its highest was AU$0.63 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$89.04M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Jul 28, 2026 which is in 140 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 222,609,240 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (150.00% Upside)
AU$1.00 (150.00% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
5.66%
Trailing 12-Months
Asset Growth
44.60%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited develops, commercializes, and markets various live biotherapeutics and complimentary medicines in Australia and internationally. It provides live biotherapeutic products under the Activated Probiotics brand; organic nutraceutical products under the Activated Nutrients brand; and sports performance and recovery products under the Activated X Performance brand. The company markets its products through community pharmacies and independent health practitioners. Biome Australia Limited was incorporated in 2018 and is based in Cremorne, Australia.
BIO Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(150.00% Upside)
Technical Analysis
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---